MeCP2 transcript-specific trans-splicing ribonuclease and its uses

By designing a trans-splicing ribozyme targeting MeCP2 RNA, the treatment challenge of Rett syndrome has been solved. This approach achieves efficient expression of normal MeCP2 RNA without inducing overexpression, thereby reducing mutant protein expression and treating Rett syndrome.

CN123125330APending Publication Date: 2026-11-17RZNOMICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580013826.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-02
Filing Date
2025-01-02
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current technologies are insufficient to effectively treat Rett syndrome, especially in the absence of the ability to efficiently express and regulate the expression of normal MeCP2 RNA without inducing intracellular WT MeCP2 overexpression.

Method used

Design trans-splicing ribozymes targeting MeCP2 RNA, with a 5'-internal guide sequence-ribozyme*-3' or 5'-internal guide sequence-exon-3' structure, which specifically bind to MeCP2 RNA to form G/U swing base pairs, bind antisense sequences to improve trans-splicing efficiency, and deliver them to target cells using viral or non-viral delivery systems.

Benefits of technology

This study achieved efficient replacement of MeCP2 mutant RNA with normal RNA under the regulation of WT MeCP2 expression within physiological levels, thereby reducing mutant protein expression and effectively treating Rett syndrome.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125330A_ABST
    Figure CN123125330A_ABST
Patent Text Reader

Abstract

This invention relates to a MeCP2 gene-specific trans-splicing ribozyme and its uses. The trans-splicing ribozyme of this invention can replace the RNA of the MeCP2 mutant gene that causes Rett syndrome with wild-type MeCP2 RNA, thereby reducing the expression of mutant MeCP2 protein, increasing the expression of wild-type MeCP2 protein, and regulating the expression of wild-type MeCP2 within a range not exceeding the physiological level, thus being beneficial for the prevention or treatment of Rett syndrome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to MeCP2 gene-specific trans-splicing ribozymes and their uses. Background Technology

[0002] According to publicly available information, it originated from Tetrahymena thermophila ( Tetrahymena thermophila Type I intron ribozymes can induce trans-splicing reactions. Under in vitro conditions, they can target and attach to the 5' exon of the exon RNA at the 3' end of the ribozyme, thereby splicing with the isolated transcript. This indicates that trans-splicing of gene transcripts associated with various genetic diseases can be used to repair these transcripts. Recent evidence also shows that in erythrocyte precursor cells from sickle cell disease patients, trans-splicing ribozymes can be used to convert the β-globin gene transcript into anti-sickling and γ-globin gene transcripts.

[0003] Trans-splicing ribozymes, as a gene therapy method, can repair the RNA of mutated genes into normal RNA. Based on the same principle, they can reduce the expression of specific genes while simultaneously expressing the target gene in the host cell. Since the ribozyme operates at the RNA level, it avoids unintended immune responses and safety issues caused by genes being mixed into random locations within the host cell genome.

[0004] Rett syndrome (RTT) is a relatively common neurodevelopmental disorder, affecting approximately 1 in 10,000 to 15,000 people. It is an X-linked dominant genetic disorder characterized by relatively normal development between 6 and 18 months of age, followed by slowed head circumference growth, cognitive and motor skill regression, loss of language, and repetitive hand-rubbing behaviors. Family history of the disease is rare, and it only affects girls; male fetuses with the condition do not survive.

[0005] In 96% to 98% of Rett syndrome patients, the cause is a mutation in the MeCP2 gene, which encodes the MeCP2 protein (Methyl-CpG binding protein 2) on the X chromosome (Xq28). The MeCP2 protein is crucial for the development of the nervous system, particularly the brain. Mutations in the MeCP2 gene reduce its production or induce structural abnormalities, ultimately leading to developmental abnormalities in specific brain regions responsible for sensory, emotional, motor, and autonomic nervous system functions. Eight main types of MeCP2 gene mutations are known in Rett syndrome, with the MeCP2 T158M and MeCP2 R106W mutations being the most common. The location and type of mutation affect the onset and severity of syndrome symptoms. Furthermore, MeCP2 duplication syndrome is caused by MeCP2 gene duplication leading to MeCP2 overexpression, manifesting as cognitive and neurodevelopmental abnormalities. MeCP2 duplication syndrome is more common in boys and is primarily maternally inherited, but rare spontaneous cases also exist.

[0006] In other words, for the treatment of Rett syndrome, ensuring that WT MeCP2 functions normally is crucial, but it is also necessary to control the overexpression of WT MeCP2. Therefore, after in-depth research, the inventors have developed a method for treating Rett syndrome by utilizing a trans-splicing ribozyme that targets MeCP2, which does not induce intracellular overexpression of WT MeCP2. Summary of the Invention

[0007] Technical problems to be solved The present invention aims to provide a MeCP2 transcript-specific trans-splicing ribonuclease and its use in treating Rett syndrome, which has excellent safety and can efficiently express normal MeCP2 RNA while regulating its expression level.

[0008] However, the technical problem to be solved by the present invention is not limited to the issues mentioned above, and other issues not mentioned will be clearly understood by those skilled in the art through the following description.

[0009] Technical solutions to the problem To address the aforementioned technical problems, this invention provides a trans-splicing ribozyme that targets MeCP2 RNA.

[0010] According to one embodiment of the present invention, the trans-splicing ribozyme may have a structure of 5'-internal guide sequence (IGS)-ribozyme*-3'.

[0011] According to another embodiment of the present invention, the trans-splicing ribozyme may have a structure of 5'-internal guide sequence (IGS)-ribozyme*-exon-3'.

[0012] According to another embodiment of the present invention, the IGS region may consist of a base sequence of 2 to 10 nt in length, which can specifically bind to MeCP2 RNA and form a G / U wobble basepair. Preferably, the IGS region may consist of a base sequence of 2 to 10 nt in length, which can complementaryly bind to regions of MeCP2 RNA containing sites +18, +31, +33, +36, +45, +54, +127, +145, +148, +162, +167, +181, +188, +211, +289, +294, +296, +304, +314, or +357, and form a G / U wobble basepair.

[0013] According to another embodiment of the present invention, the IGS region may contain, or be composed of, the base sequence of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39 or 61.

[0014] Specifically, if the reaction site of the ribozyme is the +18 site of MeCP2 RNA, then the IGS region may contain or consist of the base sequence of SEQ ID NO: 3; if the reaction site is the +31 site, then the IGS region may contain or consist of the base sequence of SEQ ID NO: 61; if the reaction site is the +33 site, then the IGS region may contain or consist of the base sequence of SEQ ID NO: 5; if the reaction site is the +36 site, then the IGS region may contain or consist of the base sequence of SEQ ID NO: 7; if the reaction site is the +45 site, then the IGS region may contain or consist of the base sequence of SEQ ID NO: 9; if the reaction site is the +54 site, then the IGS region may contain or consist of the base sequence of SEQ ID NO: 11; if the reaction site is the +127 site, then the IGS region may contain or consist of the base sequence of SEQ ID NO: 3. The IGS region may contain or consist of the base sequence of SEQ ID NO: 13 if the reaction site is +145; the IGS region may contain or consist of the base sequence of SEQ ID NO: 15 if the reaction site is +148; the IGS region may contain or consist of the base sequence of SEQ ID NO: 17 if the reaction site is +162; the IGS region may contain or consist of the base sequence of SEQ ID NO: 19 if the reaction site is +167; the IGS region may contain or consist of the base sequence of SEQ ID NO: 21 if the reaction site is +181; the IGS region may contain or consist of the base sequence of SEQ ID NO: 23 if the reaction site is +188; the IGS region may contain or consist of the base sequence of SEQ ID NO: 25 if the reaction site is +211; and the IGS region may contain the base sequence of SEQ ID NO: 19 if the reaction site is +162; the IGS region may contain or consist of the base sequence of SEQ ID NO: 19 if the reaction site is +167; the IGS region may contain or consist of the base sequence of SEQ ID NO: 21 if the reaction site is +181; the IGS region may contain or consist of the base sequence of SEQ ID NO: 23 if the reaction site is +188; and the IGS region may contain or consist of the base sequence of SEQ ID NO: 25 if the reaction site is +211. The IGS region may contain or consist of the base sequence of SEQ ID NO: 27 if the reaction site is +289; the IGS region may contain or consist of the base sequence of SEQ ID NO: 29 if the reaction site is +294; the IGS region may contain or consist of the base sequence of SEQ ID NO: 31 if the reaction site is +296; the IGS region may contain or consist of the base sequence of SEQ ID NO: 33 if the reaction site is +304; the IGS region may contain or consist of the base sequence of SEQ ID NO: 35 if the reaction site is +314; the IGS region may contain or consist of the base sequence of SEQ ID NO: 37 if the reaction site is +357; and the IGS region may contain or consist of the base sequence of SEQ ID NO: 39 if the reaction site is +357.

[0015] According to another embodiment of the present invention, the trans-splicing ribozyme may further include an antisense sequence (AS) region upstream of the IGS region, the AS region being capable of complementary binding to a portion of the MeCP2 RNA.

[0016] According to another embodiment of the present invention, the length of the AS region can be from 10 nt to 300 nt.

[0017] According to another embodiment of the present invention, the trans-splicing ribozyme may further comprise a base sequence extending in the 5' direction toward the IGS region, a portion of which may consist of a base sequence that can bind complementary to MeCP2 RNA together with the IGS region, thereby forming a P1 helix, and a portion of which may consist of a base sequence that can bind complementary to the base sequence in the 5' direction of the exon region, thereby forming a P10 helix.

[0018] This invention demonstrates that trans-splicing ribozymes targeting +33, +45, or +304 sites have high trans-splicing efficiency. Using trans-splicing ribozymes targeting +45 sites as random representatives, various P10 structures were designed for trans-splicing ribozymes targeting +45 sites, and the excellent performance of ribozymes v1 and v2 was confirmed in the neuroblastoma cell line SH-SY5Y.

[0019] Therefore, a portion of the extended base sequence in the ribozyme of the present invention used to form the P10 helix may comprise or consist of the base sequence of SEQ ID NO: 43, 45, 47 or 49.

[0020] In addition, the present invention provides a trans-splicing ribozyme expression vector, which contains the base sequence of the trans-splicing ribozyme and / or its complementary base sequence.

[0021] According to one embodiment of the present invention, the expression vector may further include a promoter operably linked to the ribozyme gene. The promoter may be a nerve cell-specific promoter, and the nerve cells include neurons, astrocytes, and oligodendrocytes. The promoter is not limited to the examples described above and may also be a viral promoter, a constitutively active promoter, a CAG promoter, etc.

[0022] Furthermore, the present invention also provides a delivery system for delivering the trans-splicing ribozyme, or a gene delivery system comprising the trans-splicing ribozyme expression vector.

[0023] Furthermore, the present invention provides a pharmaceutical composition for the prevention or treatment of Rett syndrome, comprising at least one selected from the group consisting of the trans-splicing ribozyme, a ribozyme delivery system, a vector capable of expressing the ribozyme, and a gene delivery system comprising the vector as an active ingredient.

[0024] Furthermore, the present invention provides a method for preventing or treating Rett syndrome, comprising administering to a subject at least one of the group consisting of the trans-splicing ribozyme, the trans-splicing ribozyme expression cassette, a vector capable of expressing the trans-splicing ribozyme, and a gene delivery system comprising the trans-splicing ribozyme, the expression cassette, or the vector.

[0025] According to one embodiment of the present invention, the gene delivery system may be a viral gene delivery system or a non-viral gene delivery system.

[0026] Furthermore, the present invention also provides the use of the trans-splicing ribozyme, ribozyme expression cassette, vector capable of expressing the ribozyme, or gene delivery system in the preparation of a drug for the prevention or treatment of Rett syndrome.

[0027] Invention Effects The trans-splicing ribozyme according to the present invention can reduce the expression of mutant MeCP2 protein and increase the expression of wild-type MeCP2 protein by replacing the RNA of the mutant MeCP2 gene that causes Rett syndrome with wild-type MeCP2 RNA. It can also regulate the expression of WT MeCP2 within a range not exceeding the physiological level, thereby being useful for the prevention or treatment of Rett syndrome. Attached Figure Description

[0028] Figure 1 A schematic diagram illustrating the mechanism of action of trans-splicing ribozymes targeting MeCP2 RNA.

[0029] Figure 2 This is the vector structure for expressing a trans-splicing ribozyme targeting MeCP2 RNA.

[0030] Figure 3 This is a schematic diagram of the experimental process for screening MeCP2 RNA target sites by locating them.

[0031] Figure 4This is a schematic diagram of the reaction site mapping experiment for MeCP2 RNA in vitro and in cells.

[0032] Figure 5a Results of in vitro and intracellular reaction site localization.

[0033] Figure 5b IGS and target site sequences for reaction sites selected based on localization results.

[0034] Figure 6 This diagram illustrates the various variants of MeCP2 RNA transcripts. Red squares represent the 5'UTR region, blue squares represent the ORF, and blue arrows indicate the position of the start codon (ATG).

[0035] Figure 7 The result is the in vitro trans-splicing reaction after preparing ribozymes targeting +33, +45, or +304.

[0036] Figure 8 It is a ribozyme designed with different P10 structures targeting the +45 site.

[0037] Figure 9a and Figure 9b The results show the verification of MeCP2 mRNA trans-splicing reaction in SH-SY5Y cells using ribozymes targeting the +45 site with different P10 structures; Figure 9b Figure 9c shows the results of confirming whether trans-splicing products are produced; Figure 9c shows the results of confirming the reaction sites where trans-splicing occurs in the trans-splicing products.

[0038] Figure 10 The results show the results of using ribozymes targeting the +45 site with different P10 structures to verify ribozyme activity in 293A cells.

[0039] Figures 11a to 11d The results show the levels of MeCP2 E1, MeCP2 E2, total MeCP2, ribozyme, and trans-splicing product (TSP, the replaced RNA) after co-transfection of the MeCP2 E1 expression vector with a ribozyme expression vector targeting +45 with different P10 structures in SH-SY5Y cells, as well as the results of confirming ribozyme-mediated trans-splicing reaction sites.

[0040] Figures 12a to 12dThe results show the levels of MeCP2 E1, MeCP2 E2, total MeCP2, ribozyme, and TSP in SH-SY5Y cells after co-transfection with a MeCP2 E2 expression vector and a ribozyme expression vector targeting +45 with different P10 structures, as well as the results of confirming the ribozyme-mediated trans-splicing reaction site.

[0041] Figure 13 The study demonstrates the effects of targeting +45 ribozymes on different P10 structures in iPSC-derived neurons.

[0042] Figure 14 This is a schematic diagram of an example of a trans-splicing reaction region of a ribozyme targeting +18, +33, +45, or +54 with a target MeCP2 transcript.

[0043] Best way to carry out the invention Based on the statistical results of the high incidence of MeCP2 mutations in Rett syndrome patients, the inventors conducted in-depth research on gene therapy methods for the prevention and treatment of Rett syndrome caused by MeCP2 mutations, and finally completed this invention.

[0044] Specifically, in order to obtain the target region that can effectively induce trans-splicing from the ribozyme targeting MeCP2 RNA, the inventors performed sequence analysis on the trans-splicing product generated by mixing MeCP2 RNA with a random library ribozyme, and identified +18, +31, +33, +36, +45, +54, +127, +145, +148, +162, +167, +181, +188, +211, +294, +289, +296, +304, +314, and +357 bases as reaction sites.

[0045] Meanwhile, MeCP2 has multiple variants. Therefore, when screening target sites, the inventors not only combined in vitro mapping results and the screened ribozyme trans-splicing effects, but also comprehensively considered target sites covering all variants.

[0046] The inventors prepared specific ribozymes at the +33, +45, or +304 sites of the target sites determined through a mapping process, and performed in vitro trans-splicing reactions. The results showed that the ribozymes targeting each reaction site could undergo trans-splicing reactions with MeCP2 RNA and generate reaction products.

[0047] Furthermore, the expression vectors for each ribozyme were transfected into MeCP2-positive cells SH-SY5Y, and the levels of E1 MeCP2, E2 MeCP2, and the overall E1 / E2 MeCP2 were measured. The results showed that the expression vectors transfected into these cells could express the ribozymes, and the expressed ribozymes accurately reacted with MeCP2 RNA at the target site. This specification uses the ribozyme targeting the +45 site as an example for illustration.

[0048] To improve the efficiency of trans-splicing reactions with target sites, the inventors designed various P10 structures and transfected MeCP2-positive cells with expression vectors of ribozymes containing different P10 structures to verify the reactions. The results showed that the efficiency of the P10 structures varied depending on whether the reaction was endo-MeCP2, exo-MeCP2, or the cell line. Specifically, in 293A cells, high levels of trans-splicing products were observed in ribozymes v2 and v4 when targeting endogenous MeCP2; while in SH-SY5Y cells, high levels of trans-splicing products were observed in ribozymes v1 and v2 when targeting exogenous MeCP2. In summary, v1, v2, and v4 exhibited excellent trans-splicing efficiency.

[0049] The inventors provide a trans-splicing ribozyme for reducing the expression of MeCP2 mutant protein, thereby treating Rett syndrome. The ribozyme can have a 5'-internal guide sequence (IGS)-ribozyme*-3' structure, or a 5'-IGS-ribozyme*-exon-3' structure with the target gene linked at the 3' direction. Furthermore, the ribozyme may also have an antisense sequence (AS) region complementary to MeCP2 RNA at the 5' direction of the IGS region to improve trans-splicing efficiency.

[0050] The ribozyme of the present invention can form P1 helix and / or P10 helix regions by including extended nucleotides at the 5' end of the IGS. The P1 helix is ​​a secondary structure formed by the complementary binding of the IGS region of the type I intron ribozyme and three nucleotides extending upstream therefrom with MeCP2 RNA, which can improve the binding specificity and affinity of the ribozyme to the target site. The P10 helix is ​​a secondary structure formed by the complementary binding of a 5-10 nt base sequence extending upstream of the IGS region of the ribozyme and a base sequence at the 5' end of the exon region contained in the ribozyme, which can improve the trans-splicing efficiency of the ribozyme.

[0051] In this specification, the base sequence forming the P1 helix is ​​referred to as the P1 region or P1 helical region, and similarly, the base sequence forming the P10 helix is ​​referred to as the P10 region or P10 helical region.

[0052] As used in this invention, the term "ribozyme" refers to an RNA molecule that functions as an enzyme, or a molecule composed of a protein containing that RNA molecule; it is also called an RNase or catalytic RNA. Ribozymes, as RNA molecules with a defined tertiary structure, perform chemical reactions and possess catalytic or autocatalytic properties. Some ribozymes can inhibit their activity by cleaving themselves or other RNA molecules, while others can catalyze the activity of ribosomal aminotransferases. Such ribozymes include hammerhead ribozymes, VS ribozymes, and hairpin ribozymes.

[0053] In this specification, trans-splicing refers to the connection of RNA between different genes.

[0054] In this specification, ribozymes refer to trans-splicing ribozymes that cleave MeCP2 RNA and replace it with their own RNA (especially the 3' exon region of the ribozyme), thereby inhibiting the expression of the MeCP2 mutant protein in the host cell and inducing the expression of the encoding gene in the exon region. Figure 1 In this invention, the structure of the ribozyme can be a 5'-internal guide sequence (IGS)-ribozyme. * - Exon 3' or 5' antisense sequence (AS) - IGS - Ribozyme * - Exon-3'. Ribozymes within the above structure. * A region refers to the functional region in a trans-splicing ribozyme responsible for cleaving MeCP2 RNA and / or replacing it with an exon region. Unless otherwise specified in this specification, a ribozyme refers to a ribozyme containing a region that serves as the essential functional execution region. * The trans-splicing ribozyme of the entire structure described in the region.

[0055] The gene encoded in the 3' exon region of the ribozyme in this invention can be the wild-type MeCP2 gene, and the protein may not be encoded. Since the substitution effect of the trans-splicing ribozyme depends on the level of the target RNA, the gene encoded in the exon region of the ribozyme will be expressed in dependence on the level of the target RNA.

[0056] Furthermore, this invention provides a vector for expressing a trans-splicing ribozyme targeting the MeCP2 transcript. The vector contains a trans-splicing ribozyme expression cassette targeting the MeCP2 transcript. The cassette may include a splicing donor / acceptor sequence (SD / SA sequence) spliced ​​into the 5' direction of the trans-splicing ribozyme coding region to improve ribozyme expression efficiency, and may also include a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) spliced ​​into the 3' direction of the trans-splicing ribozyme coding region. Figure 2 ).

[0057] In this specification, "vector" refers to an expression vector that can express trans-splicing ribozymes in a suitable host cell and has the necessary regulatory factors that can be operatively linked to enable the expression of the ribozyme gene insert within the vector.

[0058] In this specification, operably linked refers to the functional linkage between the nucleic acid expression regulatory sequence responsible for routine functions and the nucleic acid sequence encoding the target gene.

[0059] For example, when a ribozyme-coding sequence is operatively linked to a promoter, the expression of the ribozyme-coding sequence is influenced or regulated by the promoter. An operative link is considered operative if the promoter action drives transcription of the ribozyme-coding sequence (the ribozyme-coding sequence and its 5' promoter region). Furthermore, if the linking properties between the two sequences do not induce frameshift mutations, and the expression-regulating sequence does not inhibit ribozyme expression, then the link can be considered operative. Ooperative linking to a recombinant vector can be achieved using gene recombination techniques known in the art, and position-specific DNA splicing and ligation can be achieved using enzymes known in the art.

[0060] In addition to expression regulators such as promoters, operons, start codons, stop codons, polyadenylation signals, and enhancers, the vectors according to the present invention also include signal sequences or leader sequences for targeting membranes or secretory membranes, and can be prepared in various ways depending on the purpose. The promoter of the vector can be structural or inducible. Furthermore, the expression vector can include a selective marker for selecting host cells containing the vector, and for reproducible expression vectors, it can include an origin of replication. The vector can self-replicate or integrate with host DNA.

[0061] The vector according to the present invention is preferably a plasmid vector, a granular vector, or a viral vector, and most preferably a viral vector. Preferably, the viral vector can be a retrovirus, adenovirus, or adeno-associated virus derived from, for example, human immunodeficiency virus (HIV), murine leukemia virus (MLV), avian sarcoma / leucosis virus (ASLV), spleen necrosis virus (SNV), Rous sarcoma virus (RSV), mouse mammary tumor virus (MMTV), or a vector derived from herpes simplex virus (HSV), but the implementation is not limited to these. Most preferably, the recombinant vector according to the present invention can be a recombinant adeno-associated virus vector.

[0062] The term "promoter" as used in this invention refers to a promoter that participates in the binding of RNA polymerase, thereby initiating transcription as part of DNA. A promoter is typically adjacent to and upstream of a target gene, serving as a site for binding to either the RNA polymerase or a transcription factor of the protein that induces the RNA polymerase, thereby inducing the enzyme or protein to be located at the correct transcription start position. In other words, a promoter has a specific gene sequence located at the 5' position of the gene to be transcribed in the sense strand, allowing RNA polymerase to bind directly or via a transcription factor to the corresponding position, thereby initiating mRNA synthesis targeting the gene.

[0063] From the perspective of enhancing gene expression in viral promoters, constitutively active promoters, CAG promoters, or nerve cells, the promoter according to the present invention can be a nerve cell-specific promoter, wherein the nerve cells include neurons, astrocytes, and oligodendrocytes.

[0064] In this specification, a gene delivery system refers to a system that improves expression efficiency by increasing the delivery efficiency of ribozyme RNA or ribozyme gene and / or nucleic acid sequences into the cell. It can be divided into virus-mediated systems and non-viral systems.

[0065] Viral-mediated systems utilize viral vectors such as retroviral vectors, adenovirus vectors, adeno-associated virus vectors, and herpes simplex virus, leveraging the natural cellular invasion mechanisms of viruses to infect human cells. Compared to non-viral systems, their intracellular gene delivery efficiency is relatively high. Furthermore, while non-viral vectors, upon entering the cell, often lead to gene degradation within the lysosomes after fusion with the endosomes, viral vectors do not require lysosomes to deliver genes into the nucleus, resulting in less gene loss and higher gene delivery efficiency.

[0066] The viral vector used in this invention can function as a gene delivery vector, and as described in the description of the recombinant vector, the viral vector is derived from retroviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, etc. Such viral vectors can be combined with viral particles and then introduced into cells using transduction methods such as infection.

[0067] The non-viral system is a method that uses cationic lipids, cationic polymers, etc. as delivery vectors for nucleic acids and / or genes, or uses LNP or electroporation methods.

[0068] Cationic lipid delivery carriers primarily utilize the positive charge of cationic lipid nanoparticles (such as liposomes or lipid nanoparticles) to form complexes with negatively charged ribozyme RNA or genes, including gene expression vectors or nucleic acids. These complexes are then delivered into the cell via phagocytosis. Once delivered into the cell, the complex undergoes a single delivery from the endosome to the lysosome before detaching from the cytoplasm and being expressed. Cationic polymer delivery carriers, besides using polymers instead of lipids, exhibit similar mechanisms for delivering ribozyme RNA or genes. Representative cationic polymers include polyethyleneimine, poly-L-lysine, and chitosan.

[0069] Therefore, the complex formed by combining the recombinant vector of the present invention with a cationic lipid delivery vector or a cationic polymer delivery vector can be used as a gene delivery vector.

[0070] In this invention, the gene delivery system includes the recombinant vector described above, and can use both viral and non-viral systems, with a viral system being preferred.

[0071] On the one hand, the trans-splicing ribozyme of the present invention can target MeCP2 RNA in nerve cells to inhibit the expression of MeCP2 mutant protein. MeCP2 mutation is considered to be a major inducing gene for the pathogenesis of Rett syndrome. The trans-splicing ribozyme, ribozyme delivery system, ribozyme expression vector, and gene delivery system containing the vector of the present invention can be used as a pharmaceutical composition for the prevention or treatment of Rett syndrome.

[0072] The term “prevention” as used in this invention refers to the suppression or delay of all behaviors of Rett syndrome by using the pharmaceutical composition of this invention.

[0073] The term "treatment" as used in this invention refers to the improvement or beneficial alteration of all behaviors of Rett syndrome by using the pharmaceutical composition comprising this invention.

[0074] The pharmaceutical compositions according to the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents. Examples of pharmaceutically acceptable carriers, excipients, and diluents that can be used in pharmaceutical compositions according to the present invention include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, calcium carbonate, cellulose, methylcellulose, polyvinylpyrrolidone, water, methylparaben, propylparaben, talc, magnesium stearate, mineral oil, etc.

[0075] The pharmaceutical composition of the present invention can be administered orally or parenterally, preferably by means of a preferred method.

[0076] According to one embodiment of the present invention, the pharmaceutical composition of the present invention can be administered intravenously, intraarterially, intracerebrally, subcutaneously, intracisionally, or intrathecally. The injectable formulation of the present invention can be prepared as a ready-to-use preparation dispersed in a sterile medium, or it can be dispersed to an appropriate concentration by adding distilled water for injection before administration. Furthermore, when prepared as an injectable formulation, it can be mixed with buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, etc., to prepare single-dose ampoules or multiple dosage forms.

[0077] The dosage of the pharmaceutical composition of the present invention can vary depending on the patient's symptoms and weight, the severity of the disease, the drug formulation, the route of administration, and the timing of administration, and can be appropriately selected by those skilled in the art. The pharmaceutical composition of the present invention can be used alone or in combination with other drugs or treatments for Rett syndrome.

[0078] Methods of implementing the present invention The exemplary embodiments will now be described in detail with reference to the accompanying drawings. However, various modifications can be made to the exemplary embodiments. This disclosure is not limited to the exemplary embodiments herein. The exemplary embodiments should be understood to include all modifications, equivalents, and alternatives thereof made within the concept and scope of this disclosure.

[0079] The terminology used in the embodiments is for illustrative purposes only and is not intended to limit the scope. Unless otherwise specified in the content, a single modifier may have multiple meanings. In this specification, terms such as "comprising" or "having" are used to express the presence of the features, numbers, steps, operations, constituent elements, accessories, or combinations thereof described in the specification, and do not exclude the possibility of the presence or additional addition of one or more other features, numbers, steps, operations, constituent elements, accessories, or combinations thereof.

[0080] Unless otherwise defined, all terms, including technical or scientific terms used herein, shall have the ordinary meaning as understood by one of ordinary skill in the art to which the examples pertain. Terms commonly used, such as those defined in dictionaries, shall be understood as having the meaning in the relevant technical context and, unless explicitly defined in this specification, shall not be interpreted as having an idealized or overly formal meaning.

[0081] In describing the examples with reference to the accompanying drawings, the same reference numerals are used for the same parts, and repeated descriptions are omitted. In describing the example embodiments, detailed descriptions are omitted when it is determined that a detailed explanation of a known structure or function would unnecessarily obscure this disclosure.

[0082] [Example] Example 1. In vitro mapping To obtain various tools for removing MeCP2 mutations, MeCP2 RNA and a random ribozyme library were mixed in a test tube and reacted, followed by RT-PCR. The MeCP2 RNA site where trans-splicing occurred was identified by sequence analysis of the PCR DNA bands presumed to be trans-splicing products. Figure 3 ).

[0083] Specifically, in vitro mapping and intracellular localization were performed using E1 MeCP2 RNA or E2 MeCP2 RNA and ribozyme RNA libraries. In in vitro localization, MeCP2 RNA or intracellular mRNA was mixed with a random ribozyme library in vitro. After RT-PCR, the MeCP2 RNA region where trans-splicing occurred was identified by sequence analysis of the PCR DNA bands presumed to be trans-splicing products. More specifically, MeCP2 RNA was synthesized via in vitro transcription, or mRNA was extracted from MeCP2-expressing cells and trans-splicing ribozyme RNA libraries with random sequences (GNNNNN) at the 5' ends were synthesized via in vitro transcription. 0.1 pmol MeCP2 RNA was mixed with 1× in vitro trans-splicing reaction buffer (50 mM Heps (pH 7.0), 150 mM NaCl, 5 mM MgCl2) to prepare a total volume of 10 µL. 1 pmol of ribozyme library RNA was mixed with 1× in vitro trans-splicing reaction buffer to prepare a total volume of 9 µL. Then, 1 µL of 1 mM GTP was added to achieve a final GTP concentration of 0.1 mM. The solutions were incubated separately at 95°C for 1 min, 37°C for 3 min, and then the two solutions were combined and incubated at 37°C for 3 h. RNA was recovered from the reaction solution via phenol extraction / ethanol precipitation and then used for RT-PCR.

[0084] Next, after adding the ribozyme-specific RT primer (5'-ATGTGCTGCAAGGCGATT-3', SEQ ID NO: 56), cDNA was synthesized by reverse transcription in a volume of 20 µL. Using 2 μL of synthetic cDNA, PCR was performed for 30 cycles at 98°C for 30 seconds, 58°C for 30 seconds, and 72°C for 30 seconds, using either 10 pmol of MeCP2 mRNA-specific 5' primer #1 (5'-GCGCGCGCTCCCTCCTCT-3, SEQ ID NO: 57) or 5' primer #2 (5'-GCGCGCGCTCCCTCCTCTCGGAGAG-3', SEQ ID NO: 58) or ribozyme-specific 3' primer (5'-TGTAAAACGACGGCCAGTG-3', SEQ ID NO: 59). PCR bands were confirmed on a 2% TAE agarose gel. The detected PCR bands were compared with those from MeCP2-only RNA samples. After gel extraction and elution of different bands, base sequence analysis was used to confirm the regions in MeCP2 RNA where trans-splicing occurred. Figure 5a and Figure 5b Among the target sites confirmed through localization, considering the optimal site or intracellular efficiency in the localization results, targeting sites +33, +45, and +304 can be considered to have the best efficiency.

[0085] Example 2. Selection of the optimal target site among different MeCP2 variants MeCP2 mRNA exists in multiple variants. Therefore, in order to prepare a ribozyme that can effectively perform trans-splicing on different MeCP2 mRNA variants, the next step is to screen for the optimal target site. Figure 6 The diagram shows the untranslated region (UTR) and coding sequence (CDS) regions of 12 MeCP2 mRNA variants.

[0086] Since the +18, +31, +33, +36, and +45 bases are located in exon 1, ribozymes targeting the +18, +31, +33, +36, and +45 bases can target variants 1, 2, 3, 4, 5, 6, 8, 9, and 10.

[0087] Since the bases +127, +145, +148, +162, +167, +181, +188, and +211 are located in exon 2, ribozymes targeting the bases +127, +145, +148, +162, +167, +181, and +211 can target variants 1, 3, 4, 5, 8, 9, and X1.

[0088] Since the bases +294, +298, +304, +314, and +357 are located in exon 3, ribozymes targeting the bases +289, +294, +296, +304, +314, and +357 can target variants 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, X1, and X3.

[0089] Example 3. Confirmation of the trans-splicing effect of ribozymes targeting each reaction site. Ribozymes targeting sites +33, +45, and +304 were prepared based on the best target site or cell effect determined by mapping, and in vitro trans-splicing reactions were performed to confirm trans-splicing activity.

[0090] More specifically, 0.1 pmol of MeCP2 E1 or E2 RNA was mixed with 1 pmol of RNA from each trans-splicing ribozyme library to induce trans-splicing reactions. RNA was recovered from each reaction solution and subjected to RT-PCR. The prepared cDNA was amplified by PCR using MeCP2 RNA-specific 5' primer #1 (5'-GCGCGCGCTCCCTCCTCT-3, SEQ ID NO: 57) and ribozyme-specific 3' primer (5'-TGTAAAACGACGGCCAGTG-3', SEQ ID NO: 59) (35 cycles at 95°C for 30 s, 58°C for 30 s, and 72°C for 30 s), and each amplification product was confirmed by agarose gel electrophoresis.

[0091] The results showed that ribozymes targeting MeCP2 RNA at sites +33, +45, and +304 underwent trans-splicing reactions. Figure 7 ).

[0092] Example 4. Design and preparation of a trans-splicing ribozyme targeting the +45 site of MeCP2 RNA. To verify whether the ribozyme interacts with the +45 site from the target site of the trans-splicing reaction identified in vitro, various P10 structures were designed ( Figure 8 ).

[0093] Example 5. Confirmation of the trans-splicing effect of ribozymes targeting MeCP2 RNA. To confirm the effectiveness of the ribozyme targeting the +45 site prepared in Example 4, MeCP2-positive SH-SY5Y cells were used. The expression vector of the MeCP2-targeting ribozyme was transfected, RNA was extracted, and RT-PCR was performed to verify the trans-splicing effect.

[0094] Specifically, 4 × 10 5 Cells were seeded into 6-well plates and cultured at 37°C in a 5% CO2 incubator. 3 µg of the MeCP2-targeting ribozyme expression vector and 100 µl of Opti-MEM were added to a 1.5 ml centrifuge tube and mixed. Separately, 9 µl of Fugene HD and 100 µl of Opti-MEM were added to another 1.5 ml centrifuge tube and mixed. The contents of the two centrifuge tubes were then combined and incubated at room temperature for 15 minutes to form a complex. After 15 minutes, the centrifuge tubes were centrifuged for 10 seconds and then sprayed onto each cell for transfection. Fresh culture medium was added after 4 hours.

[0095] Cells were cultured at 37°C in a 5% CO2 incubator for 48 hours. After washing with 1×PBS, the cells were treated with 500 µl trizol to extract RNA. 5 µg of the extracted RNA was treated with 1 µl DNase I to remove gDNA, and 1 µg of this RNA was reverse transcribed to synthesize cDNA. The synthesized cDNA was used to confirm the trans-splicing product (…) via PCR. Figure 9a And through base sequence analysis, it was confirmed that a trans-splicing process had indeed occurred. Figure 9b ).

[0096] In addition, the expression vector of the ribozyme targeting MeCP2 was transfected into another MeCP2-positive cell, 293A cells, and RNA was extracted and RT-PCR was performed to verify the effect of trans splicing.

[0097] Specifically, 4 × 10 5 Cells were seeded in 6-well plates and cultured at 37°C in a 5% CO2 incubator. 3 µg of the MeCP2-targeting ribozyme expression vector and 100 µl of Opti-MEM were mixed in a 1.5 ml centrifuge tube. 6 µl of Lipofectamine P3000 was added to each centrifuge tube, and 4.5 µl of Lipofectamine 3000 and 100 µl of Opti-MEM were mixed in another 1.5 ml centrifuge tube. The contents of the two centrifuge tubes were then combined and incubated at room temperature for 15 minutes to form a liposome complex. After 15 minutes, the centrifuge tubes were centrifuged for 10 seconds and then sprayed onto each cell for transfection. Fresh medium was added after 4 hours.

[0098] After culturing at 37°C and 5% CO2 for 48 hours, cells were washed with 1×PBS and treated with 500 µl Trizol to extract RNA. 5 µg of the extracted RNA was treated with 1 µl DNase I to remove gDNA. 1 µg of the resulting RNA was used for reverse transcription to synthesize cDNA. The synthesized cDNA was used to confirm the expression levels of E1 MeCP2, E2 MeCP2, and the overall E1 / E2 MeCP2 using qPCR. The results confirmed that all ribozymes could reduce endogenous E1 and E2. Figure 10 A). There was no significant difference in expression levels among the different ribozyme designs. Confirmation of trans-splicing products indicated that all ribozyme designs produced trans-splicing products, but the extent of production varied depending on the ribozyme design. Among the compared constructs, v2 and v4 showed relatively better efficiency. Figure 10 B and Figure 10 C).

[0099] Example 6. Confirmation of the trans-splicing effect of ribozymes targeting MeCP2 RNA on E1 and E2. To confirm the efficacy of the ribozyme against MeCP2 E1 and MeCP2 E2, the MeCP2-targeting ribozyme was co-transfected with either the MeCP2 E1 or E2 expression vector into SH-SY5Y cells. Specifically, 3 µg of the MeCP2-targeting ribozyme expression vector, 0.5 µg of the MeCP2 expression vector, and 100 µl of Opti-MEM were mixed in a 1.5 ml centrifuge tube. Separately, 10.5 µl of fugene HD and 100 µl of Opti-MEM were mixed in another 1.5 ml centrifuge tube. The contents of the two centrifuge tubes were then combined and incubated at room temperature for 15 minutes. Subsequently, transfection was performed using the same method as described above, followed by RT-qPCR detection.

[0100] As a result, co-transfection with the E1 MeCP2 expression vector reduced the expression of E1 MeCP2. Figure 11a Furthermore, although the expression of each ribozyme construct differed, all of them expressed the ribozyme normally. Figure 11b Furthermore, despite differences in yield, all produced trans-splicing products. Figure 11c Sequence analysis of the trans-splicing products confirmed by qPCR confirmed that trans-splicing occurred precisely at the target site, thus proving that MeCP2 E1 was accurately replaced with the expected RNA. Figure 11d ).

[0101] Using the same method as described above for E1 MeCP2 regulation, a decrease in E2 MeCP2 expression was confirmed upon co-transfection with the E2 MeCP2 expression vector. Figures 12a to 12d ).

[0102] Therefore, the trans-splicing ribozyme targeting MeCP2 RNA according to the present invention is not limited to repairing specific MeCP2 variants, but can also replace mutation sites regardless of variant type.

[0103] Example 7. Confirmation of the effect of ribozymes targeting MeCP2 RNA on neurons Since Rett syndrome is a neurodevelopmental disorder, and the protein changes caused by mutations affect neurons, iPSC-derived neurons were used in experiments to verify the role of ribozymes in actual neurons. Two ribozyme expression vectors targeting MeCP2 were selected and transfected into neurons.

[0104] Specifically, 1.5 × 10 5 Differentiated neurons were seeded into 6-well plates and cultured at 37°C in a 5% CO2 incubator. After 3 weeks of maturation, the MeCP2-targeting ribozyme expression vector was transfected into the cells using Lipofectamine™ Stem transfection reagent. 1.25 μg of the MeCP2-targeting ribozyme expression vector and 100 μl of Opti-MEM were added to a 1.5 mL centrifuge tube and mixed. Separately, 5 μl of Lipofectamine... TM The Stem transfection reagent and 100 μl of Opti-MEM were added to another 1.5 mL centrifuge tube and mixed. The contents of the two centrifuge tubes were then combined and allowed to stand at room temperature for 10 minutes. Subsequently, RT-qPCR detection was performed using the above method.

[0105] The results confirmed a decrease in MeCP2 expression in neurons, but the decrease was not significant, and trans-splicing products were generated. Figure 13 ).

[0106] Therefore, the prepared MeCP2-targeting ribozyme is also effective against MeCP2 expressed in neurons.

[0107] The embodiments have been described above with reference to the accompanying drawings. Those skilled in the art should understand that various modifications and equivalent embodiments can be made based on these embodiments. Suitable results can also be obtained if the described techniques are performed in a different order, and / or if the constituent elements in the described systems, architectures, devices, or circuits are combined in different ways, and / or replaced or substituted by other components or their equivalents.

[0108] Therefore, other embodiments, examples, and equivalents of the claims should be interpreted as being included within the scope of protection of the claims.

Claims

1. A trans-splicing ribozyme targeting the MeCP2 transcript.

2. The trans-splicing ribozyme according to claim 1, characterized in that, The structure of the trans-splicing ribozyme is 5'-internal guide sequence (IGS)-ribozyme. * -exon-3'.

3. The trans-splicing ribozyme according to claim 2, characterized in that, The IGS region consists of a base sequence of 2 to 10 nt in length, which is complementary to a region in the MeCP2 transcript represented by SEQ ID NO: 1 containing +18, +31, +33, +36, +45, +54, +127, +145, +148, +162, +167, +181, +188, +211, +294, +289, +296, +304, +314, or +357 bases.

4. The trans-splicing ribozyme according to claim 2, characterized in that, The IGS region contains the base sequence of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39 or 61.

5. The trans-splicing ribozyme according to claim 2, characterized in that, The 5' end of the trans-splicing ribozyme also contains an antisense (AS) region that can bind complementary to a portion of the MeCP2 transcript.

6. The trans-splicing ribozyme according to claim 2, characterized in that, The exon region contains a polynucleotide sequence encoding a normal MeCP2 protein or a base sequence encoding a reporter protein.

7. The trans-splicing ribozyme according to claim 2, characterized in that, The trans-splicing ribozyme also contains a base sequence extending along the 5' direction of the IGS region. A portion of the extended base sequence consists of base sequences that can bind complementary to MeCP2 RNA along with the IGS region, thereby forming a P1 helix. A portion of the extended base sequence consists of a base sequence that can bind complementary to the base sequence in the 5' direction of the exon region, thereby forming a P10 helix.

8. The trans-splicing ribozyme according to claim 1, characterized in that, The MeCP2 transcript contains a MeCP2 mutation.

9. The trans-splicing ribozyme according to claim 8, characterized in that, The MeCP2 mutation occurs because at least one base between positions 1 and 10467 of the MeCP2 transcript represented by SEQ ID NO: 1 is replaced, deleted, or inserted.

10. A trans-splicing ribozyme expression cassette encoding the trans-splicing ribozyme according to any one of claims 1 to 9.

11. The trans-splicing ribozyme expression cassette according to claim 10, The trans-splicing ribozyme expression cassette contains a promoter sequence operatively linked to it.

12. A trans-splicing ribozyme expression vector comprising the trans-splicing ribozyme expression cassette according to any one of claims 10 to 11.

13. A recombinant virus comprising the trans-splicing ribozyme expression cassette according to any one of claims 10 to 11.

14. The recombinant virus according to claim 13, characterized in that, The virus is selected from any one of the group consisting of adenovirus, adeno-associated virus (AAV), retrovirus, lentivirus, herpes simplex virus, or vaccinia virus.

15. A nonviral gene delivery vector comprising the trans-splicing ribozyme expression cassette according to any one of claims 10 to 11.

16. A pharmaceutical composition for the prevention or treatment of Rett syndrome, characterized in that, The pharmaceutical composition comprises any one of the following as an active ingredient: the trans-splicing ribozyme of claims 1 to 9; the trans-splicing ribozyme expression cassette of claims 10 to 11; the expression vector of claim 12; and a gene delivery system comprising the expression vector.